Clinical studies in oral allergen-specific immunotherapy: differences among allergens.
Abstract
Oral immunotherapy (OIT) is a significant focus of treatment of food allergy. OIT appears to be effective in inducing desensitization, however, patients receiving OIT frequently developmild/moderate symptoms during the therapy. It has not been clearly established whether the clinical tolerance induced by OIT resembles natural tolerance. According to our data, the efficacy of OIT is different among food antigens, and it is comparatively difficult to achieve the clinical tolerance in milk OIT. Moreover, the definitive evidence of efficacy and safety with long-term therapy is limited. Further studies need to be offered to patients in clinical practice. Recently, novel treatments for food allergy, sublingual and epicutaneous immunotherapy, and combination treatment with an anti-IgE monoclonal antibody (omalizumab), have been examined in some studies. OIT combined with omalizumab increased the threshold doses of food without adverse reactions and may be of benefit in food allergy treatment. More studies are needed to demonstrate long-term safety and treatment benefits in a larger patient cohort.
© 2014 S. Karger AG, Basel
- PMID:
- 24943470
- [PubMed – indexed for MEDLINE]
LINK TO: Clinical studies in oral allergen-specific immunotherapy: differences among allergens. Int Arch Allergy Immunol. 2014;164(1):1-9.
www.ncbi.nlm.nih.gov/pubmed/24943470